|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2011-9-2
|
|
pubmed:abstractText |
Our aim was to construct and characterize (111)In-nuclear translocation sequence (NLS)-7G3, an Auger electron-emitting radioimmunotherapeutic agent that preferentially recognizes the expression of CD123 (interleukin-3 receptor [IL-3R] ?-subchain) in the absence of CD131 (IL-3R ?-subchain) displayed by leukemia stem cells.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1535-5667
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
52
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1465-73
|
|
pubmed:meshHeading |
pubmed-meshheading:21816968-Animals,
pubmed-meshheading:21816968-Antibodies, Monoclonal,
pubmed-meshheading:21816968-Bone Marrow,
pubmed-meshheading:21816968-Cell Line, Tumor,
pubmed-meshheading:21816968-Cell Nucleus,
pubmed-meshheading:21816968-Cell Survival,
pubmed-meshheading:21816968-Coordination Complexes,
pubmed-meshheading:21816968-Cytokine Receptor Common beta Subunit,
pubmed-meshheading:21816968-DNA Damage,
pubmed-meshheading:21816968-Electrons,
pubmed-meshheading:21816968-Immunoconjugates,
pubmed-meshheading:21816968-Indium Radioisotopes,
pubmed-meshheading:21816968-Interleukin-3 Receptor alpha Subunit,
pubmed-meshheading:21816968-Leukemia, Myeloid, Acute,
pubmed-meshheading:21816968-Mice,
pubmed-meshheading:21816968-Mice, Inbred NOD,
pubmed-meshheading:21816968-Mice, SCID,
pubmed-meshheading:21816968-Neoplasm Transplantation,
pubmed-meshheading:21816968-Neoplastic Stem Cells,
pubmed-meshheading:21816968-Phenotype,
pubmed-meshheading:21816968-Radioimmunotherapy,
pubmed-meshheading:21816968-Radiopharmaceuticals,
pubmed-meshheading:21816968-Tissue Distribution,
pubmed-meshheading:21816968-Tomography, Emission-Computed, Single-Photon
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Auger electron radioimmunotherapeutic agent specific for the CD123+/CD131- phenotype of the leukemia stem cell population.
|
|
pubmed:affiliation |
Department of Pharmaceutical Sciences, University of Toronto, Toronto, Ontario, Canada.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
